Frank - The instruction given to your friend regarding getting too close to family members is a standard precaution that is followed with most radioactive treatments. It looks like I3 has received approval for accelerator start-up and initial operation. As I understand it, this approval would not cover any actual production, for which a radioactive material license is required. It would appear that the company is on track for meeting their goal of starting production during 1998.
Rich
========
Monday May 11, 8:59 am Eastern Time
Company Press Release
SOURCE: International Isotopes Inc
International Isotopes Inc Receives Regulatory Approval to Initiate Operation of Accelerator
DENTON, Texas, May 11 /PRNewswire/ -- International Isotopes Inc (Nasdaq: INIS, BSE: ITL) (III), advances operations for supplying radioisotopes, pharmaceutical grade radiochemicals and contract manufacturing of radiopharmaceuticals and therapy devices. The Company announced today that the Bureau of Radiation Control of the Texas Department of Public Health has issued a registration for the operation and testing of internal proton beams in its CP-42 accelerator. The accelerator will be used for the production of F-18, I-123 and research isotopes used in the diagnosis and treatment of cancer and other diseases.
International Isotopes Inc is actively pursuing additional licenses from the Texas Department of Public Health, Bureau of Radiation Control for the operation of the LINAC accelerator for the primary production of radioisotopes and radiochemicals. ''The Company continues to keep the State and Federal Agencies informed as to progress of the Company, plans and procedures for complying with all regulations necessary to obtain prompt licenses for the manufacture and distribution of radioisotopes, pharmaceutical grade radiochemicals and finished radiopharmaceuticals,'' according to Mr. Wesley Dunn, Director of Environmental Safety and Health and Radiation Safety.
International Isotopes Inc plans to be the premier supplier of radioisotopes for the production of diagnostic and therapeutic radiopharmaceuticals for the nuclear medicine industries. The Company and its internationally recognized management team are also are developing instrumentation for radiation therapy and medical imaging.
III Safe Harbor Statement
Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the ability to meet time schedules set forth in the prospectus, development of competitive products by others and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The Company disclaims any obligation to update statements in this press release.
|
